I. Summary:

CS/SB 1124 amends section 383.14, Florida Statutes, to require the Department of Health (DOH) to adopt rules requiring every newborn in the state, at the appropriate age, to be tested for any condition included in the federal Recommended Uniform Screening Panel (RUSP) that the Genetics and Newborn Screening Advisory Council (GNSAC) advises should be included in the Newborn Screening Program’s (NSP) panel of hereditary and congenital disorders.

The DOH is required to adopt the rules to include any condition the GNSAC recommends within 18 months if a test that has been approved by the United States Food and Drug Administration (FDA), or suitable alternative that meets state guidelines, is available. If such a test is not available within 18 months, the DOH shall implement the screening as soon as such a test becomes available.

The bill also requires the DOH to adopt rules requiring the GNSAC to consider the addition of a condition in the NSP panel within one year after a condition is added to the federal RUSP.

The immediate costs to be incurred by the DOH is expected to be $1,331,492, for the implementation of testing for X-Linked Adrenoleukodystrophy (X-ALD), and SB 2500, the Senate General Appropriations Act for Fiscal Year 2017-2018, includes an appropriation for this purpose. For the implementation of future disorders, the DOH estimates a cost of $850,000 to $3 million per disorder.

The effective date of the bill is July 1, 2017.
II. Present Situation:

According to the Association of Maternal and Child Health Programs, nearly all infants born in the United States are screened by state newborn screening programs.\(^1\) From these screening programs, approximately 12,500 newborns are diagnosed annually with detectable, treatable disorders.\(^2\)

**Advisory Committee on Heritable Disorders in Children and Newborns**

At the federal level, the Secretary of the Department of Health and Human Services’ Committee on Heritable Disorders in Children and Newborns (SACHDNC) is tasked with providing the Secretary with recommendations, advice, and technical information on the most appropriate use of technologies, policies, guidelines, and standards that meet two objectives:

- Effectively reducing morbidity and mortality in newborns and children having, or at risk for, heritable disorders; and
- Enhancing the ability of state and local health agencies to provide newborn and child screening, counseling, and health care services for newborns and children having, or at risk for, heritable disorders.\(^3\)

The SACHDNC was re-established in federal law in 2014\(^4\) and the committee was chartered on May 7, 2015.\(^5\) The committee is authorized to operate through the end of the 2019 fiscal year.\(^6\) Up to 15 individuals may serve as an organizational representative on the committee. These organizations represent broad health care interests in public health, primary care, specialty care, consumer and family organizations, and professional societies.\(^7\) The committee must meet at least four times per year.\(^8\)

The SACHDNC’s Nomination and Prioritization Workgroup reviews nominated conditions to decide if sufficient evidence is available for an external evidence review by the Condition Review Workgroup (CRW). The CRW performs an independent, evidence-based review of the

---


\(^{4}\) Public Health Service Act, Title XI, s. 1111 (42 U.S.C. 300b-10), as amended by P.L. 113-240.


\(^{8}\) Supra note 6.
condition if received to determine the suitability and potential net benefit of screening for the condition. The review process includes a review of the results of controlled trials, observational studies, case studies, expert opinions, focus groups, cost-effectiveness analysis, policy analysis, and an ethical analysis.

After the CRW completes its review, the SACHDNC votes to recommend the addition of a condition to the recommended uniform screening panel (RUSP) to the Secretary. The Secretary makes the final decision to add a condition to the RUSP. States make their own determination as to which conditions they will add to their own screening programs.

Currently, the RUSP recommends screening for 32 core disorders and 26 secondary disorders. The most recently added disorder to the RUSP was in February 2016, when the Secretary approved the committee’s recommendation to add X-ALD.

**Florida Newborn Screening Program**

Florida has had a newborn screening program since 1965 and currently screens for 31 core disorders and 22 secondary disorders unless a parent objects in writing. Of these disorders, 50 are included on the federal RUSP. In Florida, the state’s Genetics and Newborn Screening and Advisory Council (GNSAC) advises the DOH on which disorders to include in Florida’s NSP panel.

Before leaving the hospital, a few drops of blood are taken from a baby’s heel, and the baby’s ears are tested for hearing. Results are sent back to the hospital and forwarded to the baby’s doctor, or the doctor can retrieve the results from a provider portal. Children’s Medical Services within the DOH will contact parents for additional testing when there is an abnormal test result.

Newborn screenings are funded by billing Medicaid and private insurance for the screening tests and a $15 fee paid by birthing facilities. Families without insurance or Medicaid coverage are not billed.

---

9 Id.
10 Id.
13 Rick Scott, Proclamation, Florida’s 50th Anniversary of Newborn Screening, (June 25, 2015) (on file with the Senate Committee on Health Policy).
14 Department of Health, Senate Bill 1124 Analysis (Apr. 3, 2017) (on file with the Senate Committee on Health Policy).
16 Id.
The 15-member GNSAC is established within the DOH. The council includes consumer members, pediatricians, medical school representatives, the State Surgeon General, a Florida Hospital Association representative, an individual with experience in newborn screening programs, an individual who represents audiologists, and a representative from the Agency for Persons with Disabilities. The council is directed to meet at least twice per year.

The GNSAC is given three purposes under the statute. The council is to advise the DOH about:

- Conditions for which testing should be included under the screening program and the genetics program;
- Procedures for collecting and transmitting specimens and recording results; and
- Methods to more effectively evaluate, coordinate, and consolidate screening programs and genetics services for children.

When the SACHDNC makes a recommendation and adds a disorder to the RUSP, the GNSAC carefully reviews the recommendation to ensure:

- The disorder is known to result in significant impairment in health, intellect, or functional ability if not treated before clinical signs appear;
- The disorder can be detected using screening methods which are accepted by current medical practice;
- The disorder can be detected prior to the infant becoming 2 weeks of age, or at the appropriate age as indicated by accepted medical practice;
- After screening for the disorder, reasonable cost benefits can be anticipated through a comparison of tangible program costs with those medical, institutional, and special educational costs likely to be incurred by an undetected population; and
- When screening for a disorder, sufficient pediatric medical infrastructure is available to provide continued services for patients’ diagnostic services and medical maintenance.

Historically, it has taken the DOH a minimum of one and a half years to implement a new disorder to the screening panel. The most recently added disorders, Severe Combined Immunodeficiency and Critical Congenital Heart Defect, took 1 year and 10 months and 2 years and 6 months, respectively, to be included in testing in Florida. Currently, there are three disorders on the RUSP that are not currently screened in Florida: X-ALD, Pompe, and Mucopolysachariidosis Type I.

When the GNSAC recommends adding a new disorder to Florida’s NSP panel, the DOH’s newborn screening laboratory prepares a fiscal impact analysis and requests a specific legislative appropriation if funding is needed. When all of the criteria are met, the condition is added to the screening program.

---

18 Section 383.14, F.S.
19 Section 383.14(5), F.S.
20 Supra note 14.
21 Supra note 14.
22 Supra note 14.
23 Supra note 14.
X-ALD was recommended for inclusion in Florida’s NSP panel by the GNSAC on February 19, 2016. Funding to implement screening has been requested through a Legislative Budget Request for Fiscal Year 2017-2018, and statewide screening will commence once a test kit is approved by the FDA that incorporates X-ALD. The test kit has been submitted to the FDA, and the approval is anticipated to be received in early 2018.24

III. Effect of Proposed Changes:

The bill amends s. 383.14, F.S., to require the DOH to adopt rules requiring every newborn in the state, at the appropriate age, to be tested for any condition included in the federal RUSP that the GNSAC advises should be included in Florida’s NSP panel.

The DOH is required to adopt the rules to include any condition the GNSAC recommends within 18 months if a FDA-approved test, or suitable alternative that meets state guidelines, is available. If such a test is not available within 18 months, the DOH shall implement the proposed screening as soon as a test offered by the FDA or alternative vendor becomes available.

The DOH is also required to adopt rules requiring the GNSAC to consider addition of a condition in the NSP panel within one year after a condition is added to the federal RUSP.

The effective date of the bill is July 1, 2017.

IV. Constitutional Issues:

A. Municipality/County Mandates Restrictions:

None.

B. Public Records/Open Meetings Issues:

None.

C. Trust Funds Restrictions:

None.

D. Other Constitutional Issues:

Under this bill, the GNSAC will review, and recommend if necessary, to the DOH new conditions that should be included on the state’s Newborn Screening Program within one year after they are added to the federal RUSP. If the GNSAC makes the recommendation to include a new condition, the DOH is required to expand the screening of that new condition statewide within 18 months of receipt of that recommendation if a test is available. This might violate the non-delegation doctrine in article 2, section 3 of the Florida Constitution because “fundamental and primary policy decisions must be made by the Legislature.”25


25 See Askew v. Cross Key Waterways, 372 So. 2d 913 (Fla. 1978).
V. Fiscal Impact Statement:

A. Tax/Fee Issues:

None.

B. Private Sector Impact:

Private health care providers and facilities may be impacted by any change in testing requirements. Tests for additional conditions may result in more results that will need follow-ups with either additional testing or referrals for specialty care.

For some conditions, FDA approved tests have not yet been developed. Laboratories that can conduct this work with non-FDA tests would be in high demand and would make these non-FDA approved tests available at a high cost initially to the states.

There may be some long-term cost savings to the health care system as health conditions are caught in the earliest stages allowing for treatment plans, intervention services, and preventive care to begin as soon as possible.

C. Government Sector Impact:

The increased costs associated with complying with the provisions of this bill is unknown. However, for the X-ALD condition recently approved by the Secretary of Health and Human Services but awaiting implementation in Florida, the DOH estimates the additional costs to be $1,331,492 annually,26 and SB 2500, the Senate General Appropriations Act for Fiscal Year 2017-2018, includes an appropriation for this purpose. These costs will be funded from amounts appropriated for the Newborn Screening Program within the DOH’s Division of Children’s Medical Services.

The Public Health Laboratory in Jacksonville has estimated increased costs of $850,000 to $3,000,000 per disorder that is added to the panel. The cost range is based on:

- Whether the testing kit has been approved by the FDA;
- Whether the test can be run on an existing test’s platform;
- Whether additional instrumentation will be required to perform the test; and
- The additional workload required to implement testing of the new condition. The exact amount is unknown and dependent upon the additional labor required to perform the tests and analyze, interpret, record, review, and report the results.27

VI. Technical Deficiencies:

None.

26 Supra note 14, at 5.
27 Supra note 14, at 5.
VII. Related Issues:

Advisory Councils

An “advisory council” is defined in state law as an advisory body created by specific statutory enactment and appointed to function on a continuing basis for the study of problems arising in a specified functional or program area of state government, and to provide recommendations and policy alternatives.28

This bill authorizes the GNSAC, an advisory council comprised of members appointed by the State Surgeon General, to recommend to the DOH new conditions that should be included in the state’s Newborn Screening Program as they are added to the federal RUSP. If this advisory panel makes a recommendation to include a condition for screening, the DOH is required to expand statewide screening of that new condition within 18 months of receiving the recommendation if a test is available from the FDA or another alternative source that meets state standards. By requiring the DOH to expand its screening program within 18 months of a recommendation, the GNSAC may be acting in more than an advisory capacity.

Implementation

Additionally, the DOH has indicated that for the last two conditions added to the newborn screening panel, the earliest the DOH has been able to implement a new test has been 22 months. The bill does not address what happens if the DOH is unable to meet the implementation deadline of 18 months.

VIII. Statutes Affected:

This bill substantially amends section 383.14 of the Florida Statutes.

IX. Additional Information:

A. Committee Substitute – Statement of Substantial Changes:

(Summarizing differences between the Committee Substitute and the prior version of the bill.)

CS by Health Policy on March 27, 2017:

The DOH is required to expand statewide screening for any condition within 18 months (rather than one year) after the council renders its advice to the DOH for additions to the screening panel, if a test approved by the United States Food and Drug Administration (FDA) or a compatible alternative test that meets state guidelines is available. If such a test is not available within 18 months of the council’s recommendation, the DOH shall implement the new screening as soon as a test approved by the FDA or an alternative vendor is available.

B. Amendments:

None.

28 Section 20.03(7), F.S.
This Senate Bill Analysis does not reflect the intent or official position of the bill’s introducer or the Florida Senate.